Company: SLNH
Filing Date: 2025-01-15
Form Type: S-1/A
Source: 0001493152-25-002391
Chunk: 298

Company: Soluna Holdings, Inc
Filing Date: 2025-01-15
Form: S-1/A
Chunk 298
---
     |      |           |   |
| Basic and Diluted EPS:                                                                                                    |     |                                  |           |   |     |      |           |   |     |                                 |           |   |     |      |           |   |
| Common shares outstanding, beginning of period, including penny warrants                                                  |     |                                  | 6,878,723 |   |     |      | 1,189,907 |   |     |                                 | 2,592,454 |   |     |      | 1,061,497 |   |
| Weighted average common shares issued during the period including penny warrants issued and outstanding as of quarter-end |     |                                  |   859,941 |   |     |      |   222,733 |   |     |                                 | 2,555,148 |   |     |      |   101,192 |   |
| Denominator for basic earnings per common shares —                                                                        |     |                                  | 7,738,664 |   |     |      | 1,412,640 |   |     |                                 | 5,147,602 |   |     |      | 1,162,689 |   |
| Weighted average common shares                                                                                            |     |                                  |     (1.29 | ) |     |      |     (5.96 | ) |     |                                 |     (6.00 | ) |     |      |    (24.16 | ) |

| F-69 |

The Company notes as continuing operations was in a net loss for the three and nine months ended September 30, 2024 and 2023, as such basic and diluted EPS is the same balance as continuing operations acts as the control amount in which would cause antidilution. Not included in the computation of earnings per share, assuming dilution, for the three and nine months ended September 30, 2024, were options to purchase 3,325shares of the Company’s common stock, 5,692nonvested restricted stock units, and 3,222,446outstanding warrants not exercised which excludes penny warrants that can be potentially exercised. These potentially dilutive items were excluded because the calculation of incremental shares resulted in an anti-dilutive effect.

Not included in the computation of earnings per share, assuming dilution, for the three and nine months ended September 30, 2023, were options to purchase 52,392shares of the Company’s common stock,